Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

470 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Position paper of Italian rheumatologists on the use of biosimilar drugs.
Atzeni F, Sebastiani M, Ricci C, Celano A, Gremese E, Iannone F, Meroni PL, Minghetti P, Sarzi-Puttini P, Ferraccioli G, Lapadula G. Atzeni F, et al. Among authors: ferraccioli g. Clin Exp Rheumatol. 2015 Jan-Feb;33(1):1-4. Epub 2014 Nov 7. Clin Exp Rheumatol. 2015. PMID: 25436597
Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability.
Iannone F, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, Caporali R, Codullo V, Ferraccioli G, Gremese E, Carletto A, Giollo A, Govoni M, Bergossi F, Galeazzi M, Cantarini L, Salaffi F, Di Carlo M, Bazzani C, Pellerito R, Sebastiani M, Ramonda R, Lapadula G. Iannone F, et al. Among authors: ferraccioli g. Clin Rheumatol. 2016 Nov;35(11):2649-2656. doi: 10.1007/s10067-016-3349-z. Epub 2016 Jul 14. Clin Rheumatol. 2016. PMID: 27418051
Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries.
Codullo V, Iannone F, Sinigaglia L, Favalli EG, Sarzi-Puttini P, Atzeni F, Ferraccioli G, Gremese E, Carletto A, Giollo A, Govoni M, Bergossi F, Galeazzi M, Cantarini L, Salaffi F, Di Carlo M, Bazzani C, Pellerito R, Sebastiani M, Ramonda R, Lapadula G, Caporali R. Codullo V, et al. Among authors: ferraccioli g. Clin Exp Rheumatol. 2017 Jul-Aug;35(4):660-665. Epub 2017 May 8. Clin Exp Rheumatol. 2017. PMID: 28516879
Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis.
Galli M, Antinori S, Atzeni F, Meroni L, Riva A, Scirè C, Adorni F, Quartuccio L, Sebastiani M, Airò P, Bazzichi L, Cristini F, Del Bono V, Manfredi A, Viapiana O, De Rosa F, Favalli E, Petrelli E, Salvarani C, Govoni M, Corcione S, Scrivo R, Sarmati L, Lazzarin A, Grassi W, Mastroianni C, Gaeta GB, Ferraccioli G, Cutolo M, De Vita S, Lapadula G, Matucci-Cerinic M, Armignacco O, Sarzi-Puttini P. Galli M, et al. Among authors: ferraccioli g. Clin Exp Rheumatol. 2017 Nov-Dec;35(6):1018-1028. Epub 2017 Nov 28. Clin Exp Rheumatol. 2017. PMID: 29185961 Review.
Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA.
Atzeni F, Sarzi-Puttini P, Sebastiani M, Panetta V, Salaffi F, Iannone F, Carletto A, Foti R, Gremese E, Govoni M, Marchesoni A, Favalli E, Gorla R, Ramonda R, Ferraccioli G, Lapadula G; GISEA group.. Atzeni F, et al. Among authors: ferraccioli g. Clin Exp Rheumatol. 2019 Jul-Aug;37(4):649-655. Epub 2019 Feb 11. Clin Exp Rheumatol. 2019. PMID: 30767865
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry.
Sebastiani M, Venerito V, Bugatti S, Bazzani C, Biggioggero M, Petricca L, Foti R, Bortoluzzi A, Balduzzi S, Visalli E, Frediani B, Manfredi A, Gremese E, Favalli E, Iannone F, Ferraccioli G, Lapadula G; Contributors. Sebastiani M, et al. Among authors: ferraccioli g. Clin Rheumatol. 2021 Oct;40(10):4039-4047. doi: 10.1007/s10067-021-05734-3. Epub 2021 Apr 21. Clin Rheumatol. 2021. PMID: 33881676
Benefit/risk of cyclosporine in rheumatoid arthritis.
Gremese E, Ferraccioli GF. Gremese E, et al. Among authors: ferraccioli gf. Clin Exp Rheumatol. 2004 Sep-Oct;22(5 Suppl 35):S101-7. Clin Exp Rheumatol. 2004. PMID: 15552522 Review.
Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy.
Caporali R, Conti F, Alivernini S, Atzeni F, Seriolo B, Cutolo M, Valesini G, Ferraccioli G, Sarzi-Puttini P, Salvarani C, Guiducci S, Zampogna G, Gremese E, Pipitone N, Scrivo R, Bugatti S, Montecucco C, Matucci-Cerinic M; Italian Society for Rheumatology. Caporali R, et al. Among authors: ferraccioli g. Clin Exp Rheumatol. 2011 May-Jun;29(3 Suppl 66):S7-14. Epub 2011 Jul 26. Clin Exp Rheumatol. 2011. PMID: 21906423 Review.
470 results